← All Sponsors
SPONSOR

Stelexis BioSciences

Total Trials
1
Recruiting
1
Phases
Phase 1
Conditions studied: AML, AdultMDS
NCT06533761 Phase 1
Recruiting

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

AML, Adult
United States, Spain View Trial →